Oxford-based Ultromics, a company that claims to be a pioneer in AI-driven cardiology diagnostics solutions, has secured $55M (nearly €48M) in a Series C funding round.
The round was co-led by L&G, Allegis Capital, and Lightrock. Existing backers, including Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University, also participated.
Contentlockr
The University of Chicago Medicine and UPMC Enterprises, the innovation, commercialisation and investment arm of the University of Pittsburgh Medical Center (UPMC), joined the round as well.
Alastair Stewart, Head of Investments, Venture Capital, at L&G, says, “Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies.”
“This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year.”
Capital utilisation
Ultromics offers an FDA-cleared, Medicare-reimbursed AI technology designed to detect Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis. These forms of heart failure are often undiagnosed or misidentified using conventional echocardiogram analysis, which relies on subjective interpretation.
The company plans to use the funds to expand its reach across the US and other markets, targeting hospitals and echo labs with high volumes of at-risk cardiac patients. It will also develop new products for additional heart conditions, build new distribution channels, and strengthen partnerships with health systems and clinical leaders.
Transforming the detection of heart failure
Founded out of the University of Oxford, Ultromics is working to address gaps in the diagnosis of complex heart conditions, particularly HFpEF and cardiac amyloidosis. Through its EchoGo platform, the company uses AI to analyse standard echocardiograms and identify disease signals that are not easily visible through manual review.
The platform generates probability scores in real time to support earlier detection and risk assessment. It is compatible with existing clinical systems and does not require new hardware, allowing it to be integrated into routine workflows.
EchoGo is reimbursed under the US Medicare programme, allowing broader access across hospitals and clinics.
Ross Upton, PhD, CEO and Founder of Ultromics, says, “The reality is, hospitals already have the data, they just haven’t had the tools to extract diagnostic signals from it. By analysing routine echocardiograms with AI, we’re helping clinicians identify high-risk patients earlier, enabling intervention before the disease progresses.”
“We’ve spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the US at a moment when health systems are actively looking to combat the growing heart failure crisis.”
Ultromics has processed over 430,000 echocardiograms and has demonstrated improved detection rates for HFpEF and cardiac amyloidosis in clinical studies. Its cardiac amyloidosis model was validated in a global study across 18 institutions and published in the European Heart Journal.
The company’s platform is being adopted by major health systems, including the University of Chicago Medicine, University Hospitals Cleveland, Northwestern University, and Mayo Clinic. Ultromics aims to help hospitals detect disease earlier, reduce unnecessary testing, and support timely treatment decisions while managing costs.
Ultromics widens US reach
Over the past year, Ultromics has expanded its platform and US market presence. In late 2024, it received FDA Breakthrough Device clearance for EchoGo Amyloidosis.
And in 2025, it launched EchoGo Score, which adds AI-based probability scoring to support HFpEF detection. Both features are now covered by Medicare for outpatient and inpatient use, supporting broader adoption across US hospitals.
“There’s a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret,” says Victor Westerlind, Managing Director at Allegis Capital.
“What’s exciting about Ultromics is how they’re closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it’s a diagnostic win that will help save lives.”
